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SummAry – Twenty to thirty percent of patients with clinical stage i testicular tumor have 
metastases in the retroperitoneum. The aim of this study was to evaluate the role of OCT4 immuno-
histochemistry in histopathologic diagnosis of lymph node metastases in patients with nonseminoma-
tous germ cell testicular tumors. All clinical stage i patients with staging laparoscopic retroperitoneal 
lymphadenectomy from 2001 until 2009 were included. Archived materials of dissected lymph nodes 
were reassessed and additional immunohistochemical staining with OCT4 antibody was performed 
in patients diagnosed as free from metastases. each slide was visually estimated for the percentage of 
tumor cells showing nuclear immunoreactivity for OCT4. The study included 93 patients, of which  
30 (32.3%) had initially positive retroperitoneal lymph nodes. Of the remaining 63 patients, materials 
were missing for 5 patients, so additional immunohistochemical staining was performed in 58 pa-
tients. Of these, two (3.4%) patients were OCT4 positive, suggesting a conclusion that they were 
initially misdiagnosed as stage i and metastasis free. OCT4 proved its value in detecting retroperito-
neal metastases. Staging laparoscopic retroperitoneal lymphadenectomy for nonseminomatous germ 
cell testicular tumors in clinical stage i is a reasonable option for selected patients.
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Introduction
The incidence of testicular cancer in Croatia has 
been increasing in the last two decades and, alongside 
several northern and western europe countries, is one 
of the highest in europe and the world. Although 
relatively rare, it is the most common solid tumor in 
young males1. The introduction of platinum-based 
multidrug chemotherapy, careful staging at the time of 
diagnosis, and prompt and appropriate treatment 
based on interdisciplinary management have resulted 
in survival rates of over 95%2,3. more than 95% of all 
testicular tumors are germ cell tumors4, and are divided 
into two large subgroups of seminoma and nonsemi-
noma. Around 30% of patients with clinical stage i 
nonseminomatous germ cell tumors (nSgCT) have 
metastatic disease in the retroperitoneum, which can-
not be detected using current imaging studies. Staging 
laparoscopic retroperitoneal lymph node dissection 
(l-rPlnd) is an operative procedure which is per-
formed for nSgCT clinical stage i5,6. Classic histo-
pathologic hematoxylin and eosin stained sections are 
a standard technique for detecting malignant lesions, 
but in rare circumstances, a reliable and sensitive im-
munohistochemical marker would be useful. OCT4 is 
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a nuclear transcription factor expressed in early em-
bryonic and germ cells. it has been utilized success-
fully in detecting neoplastic pluripotent germ cells, 
specifically seminoma, embryonal carcinoma and in-
tratubular germ cell neoplasia, unclassified (igCnu)7. 
The aim of this study was to evaluate OCT4 immuno-
histochemistry in the histopathologic diagnosis of me-
tastases in hematoxylin and eosin negative lymph 
nodes after staging l-rPlnd.
Patients and Methods
The study was retrospective and included all pa-
tients with clinical stage i nSgCT of the testis in 
whom staging l-rPlnd was performed from march 
2001 until march 2009. Orchiectomy was the initial 
treatment in all patients, and serum tumor markers 
(AfP, βhCg and ldh) were analyzed before and 
 after orchiectomy according to their half-life kinetics. 
Post-orchiectomy radiologic imaging (chest and ab-
dominal computed tomography (CT)) was performed. 
in case of no clinical signs of metastatic disease, nor-
malization of serum tumor markers, and no metastases 
or enlarged lymph nodes on CT scan, l-rPlnd was 
performed 1 to 3 months after orchiectomy. laparo-
scopic technique used is a modified template rPlnd 
with en bloc resection of lymphatic tissue. The approach 
is lateral transabdominal with the ipsilateral side ele-
vated by 45-60° from the operating table. The margins 
of the dissection were according to the modified tem-
plate, as we have previously described8. upon approval 
by the Zagreb university hospital Centre ethics 
Committee, we reassessed the archived materials of 
dissected lymph nodes and additional OCT4 immu-
nohistochemical staining was done in patients with 
negative hematoxylin and eosin lymph nodes. The 
OCT4 staining and material evaluation were per-
formed according to the previously published method7. 
The study was conducted following the principles of 
the declaration of helsinki.
Results
ninety-three patients were included in the study. 
Their mean age at the time of the procedure was 28.8 
(range 17-50) years. There were 42 left sided and 51 
right sided l-rPlnds. The mean operating time was 
180 (range 120-240) minutes. The mean number of 
lymph nodes obtained for histopathologic examina-
tion was 14.2 (range 6-34). median hospitalization 
time was 4 (range 3-10) days. There were no major 
(Clavien dindo grade ii or higher) intraoperative or 
postoperative complications during the 90-day follow 
up. One patient had prolonged lymphorrhea and none 
experienced retrograde ejaculation. Of 93 patients in-
cluded in the study, 30 (32.3%) had positive lymph 
nodes detected by classical histopathologic hematoxy-
lin and eosin stain after staging l-rPlnd initially. 
Of the remaining patients that had negative lymph 
nodes, materials were missing for five subjects, so they 
were excluded from the study. finally, lymph nodes 
from 58 patients were additionally analyzed immuno-
histochemically. Among the patients analyzed, we 
found two (3.4%) patients that showed OCT4 positiv-
Fig. 1. OCT4 positive nuclear immunoreaction 
recognizes germ cells in lymph node (OCT4 stain, 
original magnification X200).
Fig. 2. Neoplastic cells show strong nuclear staining 
reaction (OCT4 stain, original magnification X100).
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ity, both in a single lymph node (figs. 1 and 2). They 
were initially misdiagnosed as metastasis free. They 
were from the beginning of our series, to be precise, 
the 3rd and 7th patients. Both were contacted and inter-
viewed. One was disease free after orchiectomy and l-
rPlnd. The other had biochemical relapse 2 years 
after orchiectomy and l-rPlnd, βhCg was elevat-
ed, chest and abdominal CT were without enlarged 
lymph nodes. he was additionally treated with 3 cycles 
of BeP protocol and has been disease free thereafter.
Discussion
With this research, we aimed to investigate the 
value of OCT4 in detecting lymph node metastases 
after staging l-rPlnd. during the period from 
march 2001 until march 2009, staging l-rPlnd 
was performed in every patient with clinical stage i 
nSgCT according to current recommendations8. This 
resulted in a substantial number of staging laparoscop-
ic procedures performed in our department, i.e. 93 pa-
tients in 8 years. however, there has been a shift in 
practice regarding indication for this procedure over 
the last decade9, and staging retroperitoneal lymphad-
enectomy is not the first choice for the same indication 
anymore. Current guidelines advise surveillance or ad-
juvant chemotherapy, which narrows the indication for 
l-rPlnd to a group of high-risk patients that are 
not willing to undergo adjuvant chemotherapy10. Our 
results of 32.3% initially positive lymph nodes detect-
ed using l-rPlnd are similar to global trend of ret-
roperitoneal metastases in nSgCT stage i, which is 
around 30%5,10. OCT4 is a POu-domain, octamer-
binding transcription factor, also known as POu5f1 
and OCT311,12. it is a factor that enables cells to retain 
their totipotent ability13,14, which means it can be found 
in all stages of oocyte, from unfertilized oocyte to blas-
tocyst and embryonic stem cells15,16. it has also been 
found in pluripotent neoplastic germ cells which in-
clude seminoma, dysgerminoma, embryonal carcino-
ma and gonadoblastoma11,17,18. The nuclei of these neo-
plastic cells can be marked with an OCT4 antibody19. 
This is useful not only in basic research but also in 
clinical practice. it has been used to help detect igC-
nu in testicular biopsies12 and it has proven its useful-
ness in detecting testicular germ cell tumors in patients 
with cryptorchidism7. Our research proved its value in 
detecting retroperitoneal nSgCT metastases. how-
ever, the two initially misdiagnosed cases were from 
the beginning of our series, to be exact, they were the 
3rd and 7th patients in this series. The remaining cases 
were correctly diagnosed and no discrepancy between 
the original stain and OCT4 immunohistochemistry 
was found later. Although the guidelines are clear on 
the topic of staging l-rPlnd, discussion and con-
troversies on this procedure are still ongoing20. One of 
the main arguments against staging l-rPlnd is that 
around 70% of patients with clinical stage i disease 
will be overtreated. however, since l-rPlnd has 
low morbidity and mortality, it should not be discard-
ed so easily. Some authors propose a risk-adapted indi-
cation for l-rPlnd21. We share a similar opinion. in 
our hospital, the main reasons to consider staging l-
rPlnd today are as follows: 1) more than 70% of 
teratoma elements in orchiectomy histology; 2) pa-
tient’s personal preference; and 3) initially negative 
tumor markers. These are like those proposed by rass-
weiler et al.5 Since the presence of teratoma in primary 
orchiectomy histology relates to an increased incidence 
of teratoma in the retroperitoneal lymph nodes after 
chemotherapy22-24, these patients could benefit from 
staging l-rPlnd. We know that around 30% of pa-
tients with clinical stage i disease are actually clinical 
stage ii because of micro metastases in the retroperito-
neum. most of them will be treated successfully with 
chemotherapy, but there is always a portion that will 
relapse. it is important to find predictive factors for 
those relapses. Teratoma is chemotherapy-resistant 
and its presence was identified as a predictor of late 
relapses25. That is why patients with a higher percent-
age of teratomatous elements in primary specimen 
might profit from staging l-rPlnd. logothetis et al. 
report that 36% of patients with nSgCT stage ii and 
teratoma in primary specimen are more likely to re-
lapse after initial chemotherapy and would need post 
chemotherapy rPlnd versus 8% of those who do 
not26. Staging l-rPlnd in hands of a skilled surgeon 
causes less morbidity than post chemotherapy l-
rPlnd, since the complication rate for staging is 
lower as compared to post chemotherapy l-rPlnd27. 
The rationale for staging l-rPlnd in clinical stage i 
nSgCT with a high percentage of teratoma in pri-
mary specimen is based on scarce research with small 
series of patients and there are no randomized con-
trolled trials. further research on this issue is needed. 
in the interpretation of our findings, we emphasize the 
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importance of pathologist’s experience to reduce false-
negative diagnoses. Since the research shows that high 
volume providers have better surgical outcomes for 
high-risk surgeries such as l-rPlnd28, the same 
could be transposed to pathologists as well. having 
that in mind, the cost-benefit of OCT4 immunohisto-
chemistry for high volume centers might not be rea-
sonable; however, it could be valuable for low volume 
centers and novice series at the beginning of the learn-
ing curve. 
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Sažetak
OCT4 imunOhiSTOKemiJA nAKOn lAPArOSKOPSKe limfAdeneKTOmiJe  
KOd BOleSniKA S TumOrOm TeSTiSA
N. Knežević, T. Kuliš, L. Penezić, M. Ćorić, I. Krhen i Ž. Kaštelan
dvadeset do trideset posto bolesnika s tumorom testisa kliničkog stadija i. ima metastaze u retroperitoneumu. Cilj ovoga 
istraživanja bio je utvrditi vrijednosti OCT4 u patohistološkoj dijagnostici metastaza u limfnim čvorovima dobivenih lapa-
roskopskom retroperitonealnom limfadenektomijom za utvrđivanje proširenosti bolesti. u istraživanje su uključeni bolesnici 
kliničkog stadija i. koji su operirani u razdoblju od 2001. do 2009. godine. učinjena je ponovna procjena arhiviranih patohi-
stoloških materijala pričem su uzorci bolesnika za koje je prvobitno utvrđeno da nemaju metastaza dodatno imunohistoke-
mijski obrađeni protutijelima OCT4. Za svako stakalce vizualno je procijenjen postotak tumorskih stanica jezgre kojih su 
pokazale imunoreakciju za OCT4. istraživanjem su uključena 93 bolesnika od kojih je 30 (32,3%) inicijalno imalo metasta-
ze u retroperitonealnim limfnim čvorovima. Od preostala 63 bolesnika pet ih nije imalo dostupne materijale za analizu te je 
imunohistokemijsko bojenje učinjeno za 58 bolesnika. među njima dijagnosticirali smo dva (3,4%) bolesnika koji su imali 
limfne čvorove pozitivne na OCT4. njima je inicijalno utvrđen krivi stadij bolesti, čime smo zaključili kako je OCT4 potvr-
dio svoju vrijednost u otkrivanju retroperitonealnih metastaza. laparoskopska retroperitonealna limfadenektomija u svrhu 
utvrđivanja stadija bolesti predstavlja razumnu opciju za probrane bolesnike u kliničkom stadiju i. neseminomskih tumora 
zametnih stanica testisa.
Ključne riječi: Laparoskopija; Limfatične metastaze; Limfni čvor, odstranjivanje; Bojenje i označavanje preparata; Testis, 
 tumori
